COMPARISON
Glucagon vs Teduglutide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Teduglutide in 7 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Teduglutide: highest phase Phase 4 (after approval). 6 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Teduglutide | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 51 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Gattex openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2012-08-30 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | A16AX08 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Glucagon | placebo | Teduglutide | placebo |
|---|---|---|---|---|
| Abdominal pain | - | - | 31.0% | 23.3% |
| Nausea | - | - | 28.6% | 18.6% |
| Gastrointestinal stoma complication | - | - | 23.8% | 7.0% |
| Abdominal distension | - | - | 21.4% | 2.3% |
| Central line systemic infections | - | - | 16.7% | 16.3% |
| Edema peripheral | - | - | 16.7% | 4.7% |
| Urinary tract infection | - | - | 14.3% | 9.3% |
| Flatulence | - | - | 11.9% | 7.0% |
| Vomiting | - | - | 11.9% | 9.3% |
| Catheter-related infection | - | - | 11.9% | 2.3% |
Trial register Glucagon: 2 placebo-controlled trials; Teduglutide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Glucagon side effects · Teduglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Teduglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
HEAD TO HEAD
6 registered trials include both
| NCT07537686 | Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED) NOT_YET_RECRUITING · updated 2026-04-17 |
|---|---|
| NCT07400783 | TED_ORG: Study on Short Bowel Syndrome RECRUITING · updated 2026-02-10 |
| NCT03422666 | Plasma Lipoprotein Response to Glucagon-like Peptide-2 COMPLETED · updated 2022-06-14 |
| NCT03442972 | Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids COMPLETED · updated 2022-05-25 |
| NCT03860688 | Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins UNKNOWN · updated 2021-04-29 |
| NCT02099084 | Short Bowel Syndrome and Teduglutide Versus Placebo COMPLETED · updated 2016-02-22 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.